Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,209 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06150365RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
BeijingAges 18–70 - NCT06684522RecruitingEarly Phase 1
Upadacitinib for stubborn eyelid dermatitis
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
Chicago, IllinoisAges 18–70 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07006025RecruitingPhase 1
Oral THU-decitabine for MDS that has returned or not improved
This trial tests an oral combination of two drugs (THU and decitabine) for people with myelodysplastic syndromes (MDS) whose disease has come back or not responded to at least one prior standard treatment. The goal is to see if it can help control the disease.
The Bronx, New YorkAges 18 years+ - NCT06499246Recruiting
Parathyroid transplant for severe low calcium after thyroid removal
This trial tests a parathyroid gland transplant for people with severe, long-term low calcium levels after thyroid removal. It aims to help those who still have symptoms despite high-dose calcium and vitamin D supplements.
Toronto, OntarioAges 19 years+ - NCT06499025Enrolling by invitationEarly Phase 1
T-cell therapy for a type of AML with the AML1-ETO gene
This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT06456489RecruitingPhase 3
Pulse steroids for hard-to-treat rheumatoid arthritis
This trial tests whether a high-dose steroid injection can help people with rheumatoid arthritis that hasn't improved with other treatments. If you have RA that's not well controlled, this may be an option for you.
CairoAges 20–65 - NCT05552937RecruitingPhase 2
Tafasitamab plus lenalidomide for relapsed large B-cell lymphoma
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
Hangzhou, ZhejiangAges 18 years+ - NCT06337474RecruitingEarly Phase 1
CD19 CAR NK cells for hard-to-treat immune thrombocytopenia
This study tests whether a new treatment using specially designed immune cells (CD19 CAR NK cells) can help people with immune thrombocytopenia (ITP) that has not improved with standard treatments. It aims to improve platelet counts and reduce bleeding risk.
Changzhou, JiangsuAges 18–65 - NCT07283796RecruitingPhase 1
Study of HSK47977 for relapsed or refractory non-Hodgkin lymphoma
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
TianjinAges 18 years+ - NCT07059741Recruiting
Radiation, stem cell transplant, and CAR-T for aggressive B-cell lymphoma
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
Suzhou, JiangsuAges 18 years+ - NCT06404528Recruiting
Low-dose chemo under low blood sugar for advanced solid tumors
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
Wuxi, JiangsuAges 18–75 - NCT06234098RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07212686Enrolling by invitationPhase 4
Angiotensin II for severe low blood pressure in children
This study tests an IV medicine called angiotensin II (Giapreza) to raise blood pressure in children who are very sick and not responding to standard treatments. It aims to see if this medicine can help stabilize blood pressure and improve outcomes.
New Hyde Park, New YorkAges birth–18 years - NCT06822855Recruiting
Improving How We Predict Hodgkin Lymphoma Outcomes
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
Milan, MIAges 18 years+ - NCT07027202Recruiting
Early heart unloading for severe shock after ECMO
This trial tests a possible treatment to help the heart recover faster in people who need ECMO support for severe cardiogenic shock (when the heart can't pump enough blood). The treatment involves early use of a device to reduce pressure on the heart's main pumping chamber.
Clermont-FerrandAges 18 years+ - NCT06916494RecruitingPhase 1
Rutin plus immunotherapy and chemo before bladder cancer surgery
This trial tests a combination of the natural supplement rutin, an immunotherapy (tislelizumab), and two chemotherapy drugs (gemcitabine and cisplatin) before surgery for bladder cancer that didn't respond to initial chemo. It aims to see if this mix can shrink tumors better.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07321301RecruitingPhase 2
CAR T-cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new type of CAR T-cell therapy for people with B-cell lymphoma or leukemia that has not responded to standard treatments. The therapy uses a special delivery system to help the cells target and kill cancer cells.
Beijing, Beijing MunicipalityAges 14–85 - NCT07170293RecruitingPhase 2
Testing tunlametinib for NRAS-mutant solid tumors
This trial tests an experimental pill (Tunlametinib) for people with solid tumors that have a specific NRAS gene change and have stopped responding to other treatments. The goal is to see if the drug can shrink or slow the growth of these tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07704255RecruitingPhase 4
Fecal transplant for stubborn H. pylori infection
This study tries a fecal microbiota transplant (placing healthy donor stool into your gut) to get rid of stubborn H. pylori infection that hasn't been cured by standard treatments. It's for people who have failed several rounds of therapy and have a stomach condition that makes eradication important.
Chengdu, SichuanAges 18–80 - NCT07683949Enrolling by invitationPhase 1/Phase 2
Capecitabine plus lenvatinib for advanced colorectal cancer
This trial tests a combination of two oral drugs, capecitabine and lenvatinib, in people with advanced colorectal cancer that has stopped responding to three common chemotherapy drugs. It aims to see if this new combination can help shrink tumors or slow cancer growth.
Seongnam-si, Out of USAges 19–99 - NCT07433400Recruiting
Long-term study of adults with Ph+ ALL who relapsed or didn't respond
This trial follows adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that has come back or hasn't gotten better with treatment. It aims to understand how people do over time and what factors affect their health.
Pierre-BéniteAges 18 years+ - NCT07423429Recruiting
Switching to Aflibercept 8 mg for wet AMD
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Nantes, NantesAges 18 years+ - NCT07130903RecruitingPhase 2
Fruquintinib plus special radio waves for advanced colon cancer
This trial tests whether combining fruquintinib (a pill) with low-level radio waves can help people whose metastatic colorectal cancer has stopped responding to or is intolerant of standard treatments. It’s for those who have tried certain chemotherapies and anti-VEGF therapy.
Bay City, MichiganAges 22 years+
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,209 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.